MA43825A - Schémas posologiques pour le traitement d'infections fongiques - Google Patents

Schémas posologiques pour le traitement d'infections fongiques

Info

Publication number
MA43825A
MA43825A MA043825A MA43825A MA43825A MA 43825 A MA43825 A MA 43825A MA 043825 A MA043825 A MA 043825A MA 43825 A MA43825 A MA 43825A MA 43825 A MA43825 A MA 43825A
Authority
MA
Morocco
Prior art keywords
treatment
fungal infections
dosage schedules
schedules
dosage
Prior art date
Application number
MA043825A
Other languages
English (en)
French (fr)
Inventor
Kenneth Bartizal
Paul Daruwala
Jeffrey Brian Locke
Voon Ong
Taylor Sandison
Dirk Thye
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of MA43825A publication Critical patent/MA43825A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043825A 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques MA43825A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US201662436716P 2016-12-20 2016-12-20

Publications (1)

Publication Number Publication Date
MA43825A true MA43825A (fr) 2021-04-07

Family

ID=59850952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043825A MA43825A (fr) 2016-03-16 2017-03-15 Schémas posologiques pour le traitement d'infections fongiques

Country Status (8)

Country Link
US (2) US11712459B2 (enExample)
EP (2) EP3430400B1 (enExample)
JP (3) JP7224916B2 (enExample)
CN (1) CN109154603A (enExample)
CA (1) CA3017485A1 (enExample)
ES (1) ES2955711T3 (enExample)
MA (1) MA43825A (enExample)
WO (1) WO2017161016A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036778T2 (hu) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Gombaellenes szerek és alkalmazásuk
EP2827710B1 (en) 2012-03-19 2019-11-20 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CA3069423C (en) 2017-07-12 2025-04-15 Cidara Therapeutics Inc Formulations for the treatment of fungal infections
WO2019241626A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
US12060439B2 (en) 2018-10-25 2024-08-13 Napp Pharmaceutical Group Limited Polymorph of echinocandin antifungal agent
WO2020232037A1 (en) * 2019-05-16 2020-11-19 Scynexis, Inc. Antifungal agents, like ibrexafungerp for candida auris decolonization

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
EP0697879A4 (en) 1993-05-04 1998-01-14 Merck & Co Inc AMINOALKYL ETHER DERIVATIVES OF CYCLOHEXAPEPTIDES
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
CA2211138A1 (en) 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
AU766091B2 (en) 1998-12-09 2003-10-09 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1582204T3 (da) 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
IL145188A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
US6309622B1 (en) * 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
EP1172105A4 (en) * 1999-04-16 2002-09-04 Fujisawa Pharmaceutical Co ANTIFUNGAL COMPOSITIONS
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
EP1576150A4 (en) 2002-10-16 2006-05-03 Univ Texas METHOD AND COMPOSITIONS TO SAVE THE EFFECTIVENESS OF BIOLOGICALLY ACTIVE INGREDIENTS
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
EP1654036B1 (en) 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1907588B1 (en) 2005-07-26 2013-06-05 The University of Medicine and Dentistry of New Jersey Assays for resistance to echinocandin-class drugs
US20070231258A1 (en) 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
US10568859B2 (en) 2009-02-25 2020-02-25 Mayne Pharma Llc Topical foam composition
WO2010128096A1 (en) 2009-05-07 2010-11-11 Dsm Ip Assets B.V. Method for the preparation of cyclopeptides
EP2470168B1 (en) 2009-08-26 2018-01-31 BioElectron Technology Corporation Methods for the prevention and treatment of cerebral ischemia
EP2470190A4 (en) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc ECHINOCANDINDERIVATE
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
HUE036778T2 (hu) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Gombaellenes szerek és alkalmazásuk
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
EP2827710B1 (en) 2012-03-19 2019-11-20 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (en) 2013-01-18 2014-07-24 University Of Utah Research Foundation Modified release osmotic pump for ph-responsive intravaginal drug delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
US9919055B2 (en) 2013-03-15 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Sugar-linker-drug conjugates
CN112656782A (zh) 2013-05-01 2021-04-16 尼奥酷里私人有限公司 治疗细菌感染的方法
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US20180256673A1 (en) 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN110290797A (zh) 2016-11-01 2019-09-27 奇达拉治疗公司 用于预防和治疗真菌感染的单剂量方法
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
WO2018144600A1 (en) 2017-01-31 2018-08-09 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
CA3069423C (en) 2017-07-12 2025-04-15 Cidara Therapeutics Inc Formulations for the treatment of fungal infections
US20200164023A1 (en) 2017-08-03 2020-05-28 Cidara Therapeutics, Inc. Methods for preventing and treating intra-abdominal candidiasis
WO2019241626A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Also Published As

Publication number Publication date
JP7224916B2 (ja) 2023-02-20
JP7322259B2 (ja) 2023-08-07
WO2017161016A1 (en) 2017-09-21
ES2955711T3 (es) 2023-12-05
JP2019511496A (ja) 2019-04-25
CN109154603A (zh) 2019-01-04
CA3017485A1 (en) 2017-09-21
EP4268896A3 (en) 2024-01-03
EP3430400A1 (en) 2019-01-23
EP3430400A4 (en) 2019-10-30
JP2022169599A (ja) 2022-11-09
US11712459B2 (en) 2023-08-01
EP4268896A2 (en) 2023-11-01
EP3430400B1 (en) 2023-06-21
US20240108684A1 (en) 2024-04-04
US20190216885A1 (en) 2019-07-18
JP2023139211A (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
FR25C1001I1 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
MA45192A (fr) Traitement d'association
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3448875A4 (en) Compositions for the treatment of disease
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3397963A4 (en) P38 MAPK INHIBITION FOR THE TREATMENT OF CANCER
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3452060A4 (en) Combination therapy for cancer treatment
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3541417A4 (en) Combination immunotherapies for treatment of cancer
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3651801A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF MUSHROOM INFECTION
EP3495118A4 (en) Composition for treating three-dimensional object precursor
EP3766497A4 (en) Drug for treating cough
EP3716966A4 (en) ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA